BioSpace News Archive

According to a new report by Nova One Advisor, the “U.S. AI In Oncology Market” in terms of revenue was estimated to be worth USD 891.90 million in 2023 and is poised to reach USD 10,745.55 million by 2033, growing at a CAGR of 28.26% from 2024 to 2033.

Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105 IND application to the US Food and Drug Administration (FDA) on April 26, 2024.

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that’s its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.

Mesogen Inc. out of The Woodlands, Texas, has developed a transplantable Retinal Pigmented Epithelium patch to cure Macular Degeneration Blindness using autologous bone marrow-derived stem cells that carry no teratoma tumor risk and requires no immunosuppression.

Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent unmet needs present for patients grappling with these rare conditions.

Galapagos NV announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings held on 30 April 2024 were approved.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s first quarter 2024 financial results on Tuesday, May 7, 2024, after the close of the U.S. financial markets.

Ultragenyx Pharmaceutical Inc. released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024.